MC
INSY

Maverick Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

Maverick Capital’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-274,211
Closed -$2.52M – 158
2016
Q4 		$2.52M Buy
274,211
+70,351
+35% +$795K 0.03% 90
2016
Q3 		$2.4M Buy
+203,860
New +$3.1M 0.03% 91

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCP
Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Maverick Capital's INSY Position: Q1 2017 in Review

Maverick Capital sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 274,211 shares — an estimated $2.52M sold.

Maverick Capital first reported a position in INSY in Q3 2016 and held it in 2 quarters. The position peaked at $2.52M in Q4 2016. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

  • Maverick Capital reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Maverick Capital sold 274,211 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $2.52M.
  • Maverick Capital first reported a position in Insys Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Maverick Capital's Insys Therapeutics, Inc. position peaked at $2.52M in Q4 2016.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on Maverick Capital's 13F filing for Q1 2017, filed 15 May 2017.